Autologous BM/Stem Cell Transplantation in HD
| Center (reference) . | Patients (no.) . | Follow-up (yr) . | Toxic Deaths (%) . | OS (%) . | EFS (%) . | Risk Factors . |
|---|---|---|---|---|---|---|
| St Louis, Cleveland, Duke107 | 26 | 5 | 23 | 38 | 38 | Performance status, disease duration |
| UCL108 | 155 | 5 | 10 | 55 | 50 | Bulk >10 cm, >2 lines of treatment, female sex |
| Nebraska/MDA109 | 128 | 4 | 9 | 45 | 25 | Performance status, >1 chemotherapy regimen |
| Stanford110 0 RF 1 RF 2 RF 3 RF | 119 23 39 23 6 | 4 | 9 | 52 77 56-64 35-53 17 | 44 71 47-54 23-29 7 | B symptoms at relapse, extranodal disease in lung or BM, bulk disease at transplant |
| Toronto111 | 73 | 4 | 10 | 39 | ||
| 23 | 68 | No disease at transplant | ||||
| 44 | 26 | No bulk at transplant | ||||
| 6 | 0 | Bulk at transplant | ||||
| Vancouver | ||||||
| IF112 | 30 | 3.6 | 17 | 486-150 | Bleomycin lung toxicity | |
| CR113 ≥1 yr <1 yr | 58 23 35 | 2.3 | 5 | 72 | 646-150 856-150 486-150 | Duration of remission, B symptoms at relapse, extranodal disease at relapse |
| City of Hope114 | 85 | 2 | 13 | 67 | 52 | No prior chemotherapy, extranodal disease at transplant |
| Center (reference) . | Patients (no.) . | Follow-up (yr) . | Toxic Deaths (%) . | OS (%) . | EFS (%) . | Risk Factors . |
|---|---|---|---|---|---|---|
| St Louis, Cleveland, Duke107 | 26 | 5 | 23 | 38 | 38 | Performance status, disease duration |
| UCL108 | 155 | 5 | 10 | 55 | 50 | Bulk >10 cm, >2 lines of treatment, female sex |
| Nebraska/MDA109 | 128 | 4 | 9 | 45 | 25 | Performance status, >1 chemotherapy regimen |
| Stanford110 0 RF 1 RF 2 RF 3 RF | 119 23 39 23 6 | 4 | 9 | 52 77 56-64 35-53 17 | 44 71 47-54 23-29 7 | B symptoms at relapse, extranodal disease in lung or BM, bulk disease at transplant |
| Toronto111 | 73 | 4 | 10 | 39 | ||
| 23 | 68 | No disease at transplant | ||||
| 44 | 26 | No bulk at transplant | ||||
| 6 | 0 | Bulk at transplant | ||||
| Vancouver | ||||||
| IF112 | 30 | 3.6 | 17 | 486-150 | Bleomycin lung toxicity | |
| CR113 ≥1 yr <1 yr | 58 23 35 | 2.3 | 5 | 72 | 646-150 856-150 486-150 | Duration of remission, B symptoms at relapse, extranodal disease at relapse |
| City of Hope114 | 85 | 2 | 13 | 67 | 52 | No prior chemotherapy, extranodal disease at transplant |
Abbreviations: CR, complete remission; IF, induction failure; RF, risk factors; MDA, MD Anderson Tumor Institute; UCL, University College London.
Progression-free survival.